Nexalin Technology

Nexalin Technology Stock-Based Compensation

The Stock-Based Compensation (SBC) of Nexalin Technology (NXL) as of Oct 18, 2026 is 3.12 M USD. In the previous year, Stock-Based Compensation (SBC) was 3.56 M USD — a change of -12.28% (lower).

Stock-Based Compensation

3.12 MUSD

YoY

-12.28%

Last updated:

Stock-Based Compensation (SBC) of Nexalin Technology is 2025 3.12 M USD. Stock-Based Compensation (SBC) of Nexalin Technology was 2024 3.56 M USD. It decreases by -12.28% lower compared to the previous year.

The Nexalin Technology Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
562,735.00 USD
Jan 1, 2020
1.96 M USD
Jan 1, 2021
4.48 M USD
Jan 1, 2022
270,670.00 USD
Jan 1, 2023
2.41 M USD
Jan 1, 2024
3.56 M USD
Jan 1, 2025
3.12 M USD
The Nexalin Technology Stock-Based Compensation history
YEARStock-Based CompensationYoY
3.12 MUSD-12.28%
3.56 MUSD+47.53%
2.41 MUSD+791.63%
270,670.00USD-93.96%
4.48 MUSD+128.53%
1.96 MUSD+248.21%
562,735.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology Inc, headquartered in Laguna Niguel, California, designs and develops neurostimulation products within the US health care sector. Listed on September 16, 2022, the company employs six full-time staff members. Its flagship device, Generation 1, utilizes bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The non-invasive system applies a high-frequency, charge-balanced electrical current waveform via head electrodes, offering relief without adverse side effects. Additionally, Nexalin is designing clinical trials for Generation 2, targeting substance use disorders, particularly opiate abuse, as well as chronic pain, Alzheimer’s disease, and dementia. These devices operate using varying voltages and frequencies to address mental health issues effectively. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Stock-Based Compensation (SBC) of Nexalin Technology is 3.12 M USD in 2025.

Stock-Based Compensation (SBC) of Nexalin Technology changed from 3.56 M USD to 3.12 M USD, representing a -12.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nexalin Technology

All Key Metrics — Nexalin Technology